Table 1.
Patient demographics
| Patients | Age (Yrs) | Stage (Diagnosis) | Hormone Status | Treatment |
|---|---|---|---|---|
| 1 | 40 | 3 | Her2+ ER- | Pertuzumab, Trastuzumad Docetaxel, carboplatin |
| 2 | 75 | 3a | Her2- ER+ | no treatment |
| 3 | 50 | 4/Relapse | Her2- ER- | Abraxane, Gemcytabine |
| 4 | 65 | 2a | Her2+ ER+ | Pertuzumab, Transtuzumab* |
| 5 | 64 | 4/relapse | Her2- ER- | Sacituzumab, Govitecan |
| 6 | 89 | 2a | Her2- ER+ | Exemestane |
| 7 | 67 | 4/relapse | Her2- ER+ (minimal) | Sacituzumab, Govitecan |
| 8 | 55 | 3a | Her2- ER+ | Anastrozole ** |
| 9*** | 64 | 2 | Her2+ ER+ | Pertuzumab, trastuzumab, carboplatin, docetaxel |
| 10*** | 45 | 4 | ER- Her2- | Adriamycin, Cyclophosphamide |
*Post-treatment (ended 6/23), followed by endocrine therapy (Letrozol). At relapse, treated with Docetaxel and Carboplatin. Due to low tolerance, switched to listed treatment (Patient 4)
** Patient was treated between July 2020–November 2020. This followed surgery. At blood draw, patient was on endocrine therapy with Anastrozole. Currently no active disease
***Patients 9 and 10 blood samples were analyzed with in vitro studies (Table 3)